

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ID APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/224,781 01/04/99 LIBIN В 1059-007 **EXAMINER** HM22/1005 JAMES V COSTIGAN ROSE, S PAPER NUMBER **ART UNIT** HEDMAN GIBSON & COSTIGAN 1185 AVENUE OF THE AMERICAS 14 16.24 NEW YORK NY 10036 DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

10/05/00

	Application No.	Applicant(s)	,		
Office Action Summary	09/224781	LIBIA	/		
Office Action Summary	Examiner S 1927	R. 58	Group Art Unit		
—The MAILING DATE of this communication appe		beneath the c	orrespondence addre	ss—	
Period for Reply	i				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET $^\circ$ OF THIS COMMUNICATION.	TO EXPIRE	MONTH(S	S) FROM THE MAILING	DATE	
 Extensions of time may be available under the provisions of 37 CFR from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a If NO period for reply is specified above, such period shall, by defaul Failure to reply within the set or extended period for reply will, by sta 	reply within the statutory mir t, expire SIX (6) MONTHS fi	nimum of thirty (30) rom the mailing da) days will be considered tir te of this communication .		
Status					
Responsive to communication(s) filed on AVS	7 2000			•	
☐ This action is FINAL.					
□ Since this application is in condition for allowance except accordance with the practice under Ex parte Quayle, 19			the merits is closed	in	
Disposition of Claims					
☑ Claim(s) /8 € 32			is/are pending in the application.		
Of the above claim(s)			is/are allowed.		
□ Claim(s)					
□ Claim(s)					
□ Claim(s)		is/are	objected to.		
D/ Claim(s) 18 C 32	8 6 32			lection	
			ement.		
Application Papers	5 : 570.040				
 □ See the attached Notice of Draftsperson's Patent Drawi □ The proposed drawing correction, filed on 		l 🗆 diaanana.			
☐ The drawing(s) filed on is/are obje	• •	• •	70.		
☐ The specification is objected to by the Examiner.	olou to by the Examino.	•			
☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. § 119 (a)-(d)					
☐ Acknowledgment is made of a claim for foreign priority u	under 35 U.S.C. § 11 9(a	a)-(d).			
☐ All ☐ Some* ☐ None of the CERTIFIED copies o☐ received.	f the priority documents	have been			
 received in Application No. (Series Code/Serial Numl received in this national stage application from the In 	· ·				
*Certified copies not received:			<u> </u>		
Attachment(s)					
☐ Information Disclosure Statement(s), PTO-1449, Paper	No(s)	☐ Interview Summary, PTO-413			
☐ Notice of Reference(s) Cited, PTO-892	☐ Notice of Informal Patent Application, PTO-15				
☐ Notice of Draftsperson's Patent Drawing Review, PTO-9	18 □ Other				

Office Action Summary

U. S. Patent and Trademark Office PTO-326 (Rev. 9-97)

Part of Paper No.

Serial No. 09/224,781

Art Unit 1614

The reply filed on August 7, 2000 is not fully responsive to the prior Office action because of the following omission(s) or matter(s): There is no responsive election as required. See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. Extensions of this time period may be granted under 37 CFR 1.136(a).

The claims remaining in this application clearly include:

I. Claims 18-22, drawn to treating herpetic (virus) infections with both (a) Triclosan and (b) a cationic antimicrobial agent.

Claim 19 is drawn to a Markush group of (b) cationic antimicrobial agents.

II. Claims 23, 24, 25 and 27-30 are drawn to treating fungus infections with both: (a) Triclosan and (b) cationic antimicrobial agent.

Claim 27 is drawn to a Markush group of (b) cationic antimicrobial agents.

Claims 20, 28, 31 and 32 (claims 30 and 31 renumbered, Rule 126) are drawn to Triclosan and the cetylpyridinium chloride species of cationic antimicrobial agent.

Serial No. 09/224,781

Art Unit 1614

Pages 10 and 11 of the March 2, 2000 Office action clearly imposes an election of species requirement.

Applicant was clearly required to elect one species each of:

- (a) a cationic antimicrobial agent;
- (b) a species of disease selected from one of mucositis, fungus disease infection, or herpetic infection.

 While mucositis has been cancelled, there has been no response to the outstanding election of species requirement as imposed.

The terminal disclaimers have been accepted.

There is prior art of record (which should be reviewed), describing fungus infections, or herpes infections, treated with encompassed species of (b) cationic antimicrobial agents, (not necessarily cetylpyridinium chloride), i.e. chlorhexidine, and by Triclosan.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shep Rose whose telephone number is (703) 308-4609. The examiner can normally be reached on Monday-Thursday from 7:30 A.M. to 6 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Cintins, can be reached on (703) 308-4725. The fax phone number for this Group is (703) 308-4556.

Serial No. 09/224,781

Art Unit 1614

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

8hap Ru

Shep Rose Senior Primary Examiner Art Unit 1614

SKR:cdc October 3, 2000

SHEP K. ROSE PRIMARY EXAMINER GROUP 1200